AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

AveXis is now known as Novartis Gene Therapies, marking another milestone in their journey to be the world’s leading gene therapy company.

Novartis has renamed the previously acquired AveXis to Novartis Gene Therapies. The change signifies the growing importance of gene therapy to building a leading, focused medicines company with advanced therapy platforms.

Find out more here.

Categories: Ecosystem News